ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

darolutamide

Also written as “Darolutamide”, “Darolutamide (Nubeqa, BAY1841788)” and “Darolutamide (BAY1841788, Nubeqa)”.

Its studies are mostly in Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant · Bulbo-Spinal Atrophy, X-Linked · Neoplasms · Neoplasm Metastasis, led by 2 companies.

Drug pageDarolutamide: every studyAll 77 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 21, 202220 company-led studies, 4 open or runningNext primary completion: Jul 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayerits history only164 open or runningphase 4since Apr 21, 2022Jul 22, 2014Jul 30, 2027phase 3 · NCT05794906
Orion Corporation, Orion Pharma40 open or runningphase 2since Mar 7, 2011Mar 7, 2011none ahead

Also a collaborator on its studies: Keenova Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Orion Corporation, Orion Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Mar 7, 2011First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT01317641 · 136 enrolled · United States, Czech Republic, Estonia and more
  2. Sep 1, 2011Phase 2 study in Prostatic NeoplasmsNCT01429064 · 76 enrolled · United States, Czech Republic, Estonia and more
  3. Feb 4, 2013Phase 1 study in Prostatic NeoplasmsNCT01784757 · 30 enrolled · Latvia
  4. Mar 24, 2015Phase 1 study in HealthyNCT02418650 · 12 enrolled · United Kingdom
  5. Jun 9, 2016Named darolutamideINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ODM-201

TargetBeta

AR →read by rule
“A formulation containing an androgen receptor (AR) antagonist ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
rezvilutamideruleJiangsu HengRui Medicinephase 313
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 4 Orion Corporation, Orion Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02418650Healthy · United Kingdom1CompletedMay 201512
NCT01784757Prostatic Neoplasms · Latvia1CompletedAug 201330
NCT01429064Prostatic Neoplasms · United States, Czech Republic, Estonia and more2CompletedNov 201576
NCT01317641Prostatic Neoplasms · United States, Czech Republic, Estonia and more2CompletedJul 2013136

How it is read

Names in the registry

  • “Darolutamide”, 6 entries
  • “Darolutamide (Nubeqa, BAY1841788)”, 5 entries
  • “Darolutamide (BAY1841788, Nubeqa)”, 2 entries
  • “BAY1841788 (ODM-201)”, 2 entries
  • “ODM-201”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.